ASH 2014 | ASH 2014: Phase Ib study of daratumumab in combination with backbone regimens in myeloma

Maria-Victoria Mateos

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos discusses an open-label, multicentre, phase Ib study of the safety, tolerability and dose regimen of the anti-CD38 monoclonal antibody, daratumumab, in combination with backbone regimens in patients with multiple myeloma. Backbone regimens include bortezomib-dexamethasone, bortezomib-thalidomide-dexamethasone, bortezomib-melphalan-prednisone and pomalidomide-dexamethasone.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter